T1	PROC 57 63	quimio
#1	AnnotatorNotes T1	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T2	PROC 78 84	quimio
#2	AnnotatorNotes T2	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T3	PROC 128 152	tratamiento post-cirugía
#3	AnnotatorNotes T3	C2243054; aftercare following surgery; Health Care Activity
T4	DISO 1210 1221	metastásico
#4	AnnotatorNotes T4	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T5	PROC 226 254	Estudio fase 3, aleatorizado
T6	PROC 259 285	quimioterapia neoadyuvante
T7	PROC 300 326	quimioterapia neoadyuvante
T8	CHEM 331 340	Nivolumab
#5	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 343 352	Nivolumab
#6	AnnotatorNotes T9	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	PROC 379 414	tratamiento continuado post-cirugía
T11	CHEM 419 428	Nivolumab
#7	AnnotatorNotes T11	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 431 440	Nivolumab
#8	AnnotatorNotes T12	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	DISO 471 504	cáncer de vejiga músculo-invasivo
T14	ANAT 488 495	músculo
#9	AnnotatorNotes T14	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T15	DISO 529 545	Cáncer de vejiga
#10	AnnotatorNotes T15	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T16	DISO 546 579	Cáncer de vejiga músculo-invasivo
T17	ANAT 563 570	músculo
#11	AnnotatorNotes T17	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T18	DISO 622 626	CVMI
#12	AnnotatorNotes T18	C4725841; Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Neoplastic Process
T19	PROC 674 676	RM
#13	AnnotatorNotes T19	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T20	PROC 683 697	diagnosticados
#14	AnnotatorNotes T20	C0011900; Diagnosis; Diagnostic Procedure
T21	PROC 701 706	RTUTV
#15	AnnotatorNotes T21	C0401496; Transurethral resection of bladder neoplasm; Therapeutic or Preventive Procedure
T22	ANAT 821 830	urotelial
#16	AnnotatorNotes T22	C0227598; Urothelium; Tissue
T23	CHEM 89 93	Nivo
T24	PROC 895 897	CR
#17	AnnotatorNotes T24	C0194401; Complete cystectomy; Therapeutic or Preventive Procedure
T25	PROC 992 1016	tratamiento neoadyuvante
#18	AnnotatorNotes T25	C0600558; Neoadjuvant Therapy; Therapeutic or Preventive Procedure
T26	CONC 1121 1137	Pruebas clínicas
T27	ANAT 1141 1143	GL
#19	AnnotatorNotes T27	C0024204; lymph nodes; Body Part, Organ, or Organ Component | C1269047; Entire lymph node; Body Part, Organ, or Organ Component lymph nodes
T28	DISO 1182 1198	cáncer de vejiga
#20	AnnotatorNotes T28	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T29	PROC 1245 1266	tratamiento sistémico
T30	PROC 1268 1280	radioterapia
#21	AnnotatorNotes T30	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T31	PROC 1283 1290	cirugía
#22	AnnotatorNotes T31	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T32	DISO 1307 1323	cáncer de vejiga
#23	AnnotatorNotes T32	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T33	PROC 1333 1338	RTUTV
#24	AnnotatorNotes T33	C0401496; Transurethral resection of bladder neoplasm; Therapeutic or Preventive Procedure
T34	PROC 1341 1349	biopsias
#25	AnnotatorNotes T34	C0005558; Biopsy; Diagnostic Procedure
T35	CHEM 1381 1391	cisplatino
#26	AnnotatorNotes T35	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T36	DISO 1401 1422	neuropatía periférica
#27	AnnotatorNotes T36	C0031117; Peripheral Neuropathy; Disease or Syndrome
T37	DISO 1425 1441	pérdida auditiva
#28	AnnotatorNotes T37	C1384666; hearing impairment; Disease or Syndrome
T38	PROC 1442 1454	audiométrica
#29	AnnotatorNotes T38	C0004286; Audiometry; Diagnostic Procedure
T39	PROC 1480 1506	aclaramiento de creatinina
#30	AnnotatorNotes T39	C0373595; Creatinine clearance measurement; Laboratory Procedure
T40	CHEM 443 453	BMS-986205
#31	AnnotatorNotes T40	C4683552; BMS-986205; Immunologic Factor · Pharmacologic Substance
T41	ANAT 481 487	vejiga
#32	AnnotatorNotes T41	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T42	ANAT 539 545	vejiga
#33	AnnotatorNotes T42	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T43	ANAT 556 562	vejiga
#34	AnnotatorNotes T43	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T44	PROC 669 671	TC
#35	AnnotatorNotes T44	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T45	PROC 735 765	pruebas de imagen radiológicas
T46	PROC 966 968	CR
#36	AnnotatorNotes T46	C0194401; Complete cystectomy; Therapeutic or Preventive Procedure
T47	ANAT 1192 1198	vejiga
#37	AnnotatorNotes T47	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T48	PROC 1526 1551	fórmula de Cockroft-Gault
#38	AnnotatorNotes T48	C4064204; renal creatinine clearance predicted by Cockroft-Gault formula; Laboratory Procedure
T49	ANAT 1317 1323	vejiga
#39	AnnotatorNotes T49	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T50	PROC 1508 1513	AclCr
T51	CHEM 1496 1506	creatinina
#40	AnnotatorNotes T51	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T52	ANAT 1563 1568	orina
#41	AnnotatorNotes T52	C0042036; Urine; Body Substance
T53	DISO 199 203	CVMI
#42	AnnotatorNotes T53	C4725841; Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Neoplastic Process
T54	CHEM 355 365	BMS-986205
#43	AnnotatorNotes T54	C4683552; BMS-986205; Immunologic Factor · Pharmacologic Substance
T55	CHEM 171 181	BMS-986205
#44	AnnotatorNotes T55	C4683552; BMS-986205; Immunologic Factor · Pharmacologic Substance
T56	CHEM 104 114	BMS-986205
#45	AnnotatorNotes T56	C4683552; BMS-986205; Immunologic Factor · Pharmacologic Substance
T57	CHEM 164 168	Nivo
T58	CHEM 157 161	Nivo
T59	Date 13 17	2017
T60	Neg_cue 100 103	sin
T61	Date 140 152	post-cirugía
#46	AnnotatorNotes T61	C0032790; Postoperative Period; Temporal Concept
T62	LIVB 185 194	pacientes
#47	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	Date 402 414	post-cirugía
#48	AnnotatorNotes T63	C0032790; Postoperative Period; Temporal Concept
T64	LIVB 457 466	pacientes
#49	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T65	LIVB 608 617	Pacientes
#50	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T68	LIVB 872 880	paciente
#51	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	LIVB 906 914	oncólogo
#52	AnnotatorNotes T69	C0259990; Oncologists; Professional or Occupational Group | C1555767; Physicians - Internal Medicine - Medical Oncology; Professional or Occupational Group
T70	LIVB 919 926	urólogo
#53	AnnotatorNotes T70	C0260314; Urologists; Professional or Occupational Group
T73	Neg_cue 1226 1233	Tampoco
T75	Neg_cue 1355 1357	No
T77	Duration 1572 1580	24 horas
T80	PHYS 1433 1441	auditiva
#54	AnnotatorNotes T80	C0018767; Hearing; Physiologic Function
T66	PROC 1563 1580	orina de 24 horas
#55	AnnotatorNotes T66	C0201978; Creatinine measurement, 24 hour urine; Laboratory Procedure
T67	PROC 1020 1036	Estado funcional
#56	AnnotatorNotes T67	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T71	PROC 793 803	histología
#57	AnnotatorNotes T71	C0344441; Histology Procedure; Laboratory Procedure (?)
A1	Assertion T56 Negated
A2	Assertion T29 Negated
A3	Assertion T30 Negated
A4	Assertion T31 Negated
A5	Assertion T35 Negated
A6	Status T29 History_of
A7	Status T30 History_of
A8	Status T31 History_of
A9	Status T33 History_of
A10	Status T34 History_of
#58	AnnotatorNotes T5	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
#59	AnnotatorNotes T23	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#60	AnnotatorNotes T58	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#61	AnnotatorNotes T57	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#62	AnnotatorNotes T7	C5392214; Neoadjuvant Chemotherapy; Therapeutic or Preventive Procedure
#63	AnnotatorNotes T6	C5392214; Neoadjuvant Chemotherapy; Therapeutic or Preventive Procedure
#64	AnnotatorNotes T13	C4725841; Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Neoplastic Process
#65	AnnotatorNotes T16	C4725841; Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Neoplastic Process
#66	AnnotatorNotes T45	C0043299; Diagnostic radiologic examination; Diagnostic Procedure | C1962945; Radiographic imaging procedure; Diagnostic Procedure
#67	AnnotatorNotes T50	C0373595; Creatinine clearance measurement; Laboratory Procedure
R1	Combined_with Arg1:T2 Arg2:T23	
R2	Combined_with Arg1:T23 Arg2:T56	
R3	Negation Arg1:T60 Arg2:T56	
R4	Before Arg1:T1 Arg2:T3	
R5	Before Arg1:T2 Arg2:T3	
R6	Overlap Arg1:T3 Arg2:T61	
T72	Quantifier_or_Qualifier 64 68	sola
R7	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T72	
R8	Combined_with Arg1:T3 Arg2:T58	
R9	Combined_with Arg1:T3 Arg2:T57	
R10	Combined_with Arg1:T57 Arg2:T55	
R11	Experiences Arg1:T62 Arg2:T1	
R12	Experiences Arg1:T62 Arg2:T2	
R13	Experiences Arg1:T62 Arg2:T3	
R15	Experiences Arg1:T62 Arg2:T57	
R16	Experiences Arg1:T62 Arg2:T53	
T74	Quantifier_or_Qualifier 286 290	sola
R17	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T74	
R18	Combined_with Arg1:T7 Arg2:T8	
R19	Combined_with Arg1:T7 Arg2:T9	
R20	Combined_with Arg1:T9 Arg2:T54	
R21	Before Arg1:T6 Arg2:T10	
R22	Before Arg1:T7 Arg2:T10	
R23	Overlap Arg1:T10 Arg2:T63	
R24	Overlap Arg1:T11 Arg2:T63	
R25	Overlap Arg1:T12 Arg2:T63	
R26	Overlap Arg1:T40 Arg2:T63	
R27	Combined_with Arg1:T10 Arg2:T11	
R28	Combined_with Arg1:T10 Arg2:T12	
R29	Combined_with Arg1:T12 Arg2:T40	
R30	Location_of Arg1:T41 Arg2:T13	
T76	Observation 488 504	músculo-invasivo
#68	AnnotatorNotes T76	C4725840; Muscle Invasion; Finding
R33	Location_of Arg1:T14 Arg2:T76	
R35	Location_of Arg1:T43 Arg2:T16	
T78	Observation 563 579	músculo-invasivo
#69	AnnotatorNotes T78	C4725840; Muscle Invasion; Finding
R36	Location_of Arg1:T17 Arg2:T78	
R38	Location_of Arg1:T42 Arg2:T15	
R39	Experiences Arg1:T64 Arg2:T6	
R40	Experiences Arg1:T64 Arg2:T7	
R41	Experiences Arg1:T64 Arg2:T9	
R42	Experiences Arg1:T64 Arg2:T10	
R43	Experiences Arg1:T64 Arg2:T12	
R44	Experiences Arg1:T64 Arg2:T13	
T79	Result_or_Value 659 665	<10 mm
R46	Has_Result_or_Value Arg1:T18 Arg2:T79	
R47	Experiences Arg1:T65 Arg2:T18	
R48	Experiences Arg1:T65 Arg2:T44	
R49	Experiences Arg1:T65 Arg2:T19	
R50	Before Arg1:T21 Arg2:T20	
R51	Experiences Arg1:T65 Arg2:T21	
R52	Experiences Arg1:T65 Arg2:T45	
T81	Observation 647 649	T2
#70	AnnotatorNotes T81	C0475373; Tumor stage T2; Finding
T82	Observation 650 653	T4a
#71	AnnotatorNotes T82	C0475395; Tumor stage T4a; Finding
R55	Overlap Arg1:T18 Arg2:T81	
R56	Overlap Arg1:T18 Arg2:T82	
T83	Observation 655 657	N0
#72	AnnotatorNotes T83	C0441959; Node stage N0; Finding
R57	Overlap Arg1:T18 Arg2:T83	
R69	Experiences Arg1:T68 Arg2:T24	
R70	Experiences Arg1:T68 Arg2:T46	
R71	After Arg1:T46 Arg2:T25	
R72	After Arg1:T24 Arg2:T25	
T84	CONC 1041 1075	Eastern Cooperative Oncology Group
#73	AnnotatorNotes T84	C1520224; ECOG performance status; Intellectual Product
T85	CONC 1077 1081	ECOG
#74	AnnotatorNotes T85	C1520224; ECOG performance status; Intellectual Product
T86	Result_or_Value 1086 1091	0 o 1
R73	Has_Result_or_Value Arg1:T85 Arg2:T86	
R74	Has_Result_or_Value Arg1:T84 Arg2:T86	
R75	Used_for Arg1:T84 Arg2:T67	
R76	Used_for Arg1:T85 Arg2:T67	
T87	Result_or_Value 1144 1153	positivos
#75	AnnotatorNotes T87	C1446409; Positive; Finding
R78	Location_of Arg1:T27 Arg2:T26	
T88	Result_or_Value 1155 1178	≥ 10 mm en el eje corto
R79	Has_Result_or_Value Arg1:T26 Arg2:T88	
R80	Location_of Arg1:T47 Arg2:T28	
R81	Before Arg1:T28 Arg2:T4	
R82	Negation Arg1:T73 Arg2:T29	
R83	Negation Arg1:T73 Arg2:T30	
R84	Negation Arg1:T73 Arg2:T31	
#76	AnnotatorNotes T29	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R85	Location_of Arg1:T49 Arg2:T32	
R86	Negation Arg1:T75 Arg2:T35	
T89	Quantifier_or_Qualifier 1458 1476	grado 2 o superior
R89	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T89	
R93	Location_of Arg1:T52 Arg2:T66	
R94	Overlap Arg1:T66 Arg2:T77	
T90	Result_or_Value 1582 1593	< 50 ml/min
R95	Has_Result_or_Value Arg1:T39 Arg2:T90	
R96	Has_Result_or_Value Arg1:T50 Arg2:T90	
R97	Before Arg1:T66 Arg2:T39	
T91	Observation 679 681	M0
#77	AnnotatorNotes T91	C0445034; M0 Stage Finding; Finding
R101	Overlap Arg1:T18 Arg2:T91	
R102	Experiences Arg1:T68 Arg2:T25	
R103	Causes Arg1:T28 Arg2:T87	
#78	AnnotatorNotes T72	C0205171; Singular; Quantitative Concept
#79	AnnotatorNotes T74	C0205171; Singular; Quantitative Concept
#80	AnnotatorNotes T26	C5554846; Clinical Evidence; Idea or Concept
R32	Has_Result_or_Value Arg1:T26 Arg2:T87	
T92	Route 1257 1266	sistémico
R14	Has_Route_or_Mode Arg1:T29 Arg2:T92	
#81	AnnotatorNotes T92	C0205373; Systemic; Functional Concept
T93	Observation 810 846	componente urotelial es predominante
A11	Assertion T93 Hypothetical
A12	Experiencer T69 Other
A13	Experiencer T70 Other
A14	Experiencer T68 Patient
A15	Experiencer T62 Patient
A16	Experiencer T64 Patient
A17	Experiencer T65 Patient
